Explore HCV and Drug User Health Center of Excellence Learning Pathways (LP)
Foundations of Buprenorphine for Opioid Use Disorder (Online)
Description:
This three-part learning pathway will provide attendees with knowledge on how to prescribe buprenorphine in New York State. It will cover the goals and principles of buprenorphine treatment for opioid use disorder as well as training requirements in order to prescribe buprenorphine. This pathway will discuss the pharmacology of buprenorphine as compared with other medications for opioid use disorder and review best practice for initiation, dose stabilization, maintenance and discontinuation. It will provide case studies to illustrate how buprenorphine treatment can be delivered in various clinical settings. Attendees will receive a Pathway Certification of Completion after completing the series.
Trainings Included:
- Buprenorphine Initiation for Beginners
- Buprenorphine in Practice: A Case-based Discussion
Click here to register
Trainings to Satisfy the DEA Education Mandate (Online)
Description:
In June 2023, the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) announced a one-time requirement of eight hours of training on the treatment and management of patients with opioid or other substance use disorder for practitioners who are applying for or renewing their DEA license. As an ACCME-accredited organization, CEI recommends the following courses to meet the DEA requirement.
Refer to official communication from the DEA and SAMHSA for more information:
- https://deadiversion.usdoj.gov/pubs/docs/MATE_Training_Letter_Final.pdf
- https://www.samhsa.gov/substance-use/treatment/statutes-regulations-guidelines/mate-act/curricular-elements-training
Trainings Included:
- Clinical Practice Guidelines for the Treatment of Alcohol Use Disorder - V100
- Tobacco Use Disorder Treatment among People Who Use Drugs
- Stimulant Use Disorder: Clinical Practice Guidelines for the Primary Care Provider
- Pain Management for People Who Use Opioids
- Xylazine: What Clinicians Need to Know
- Integrating Harm Reduction into Every Clinical Encounter